首頁 > 市場調查報告書 > 製藥

非專利藥

市場調查報告書

商品編碼

1954435

日本非專利注射劑市場：規模、佔有率、趨勢和預測：按治療領域、包裝容器、銷售管道和地區分類，2026-2034年

Japan Generic Injectables Market Size, Share, Trends and Forecast by Therapeutic Area, Container, Distribution Channel, and Region, 2026-2034

出版日期: 2026年02月01日 | 出版商:

IMARC | 英文 138 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2025年，日本非專利達19億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到71億美元，2026年至2034年的複合年成長率（CAGR）為16.05%。推動這一市場成長的因素包括：高價值注射劑專利到期、國民健康保險（NHI）報銷政策的有利續期、國內注射劑產品組合的擴大、以成本為導向的採購改革、臨床接受度的提高、日本藥品和醫療設備管理局（PMDA）監管信譽的提升、電子處方箋的推廣、藥物監測工作的加強，以及腫瘤科、腎內科和急診科的強化科。

日本非專利注射藥品市場趨勢：

高價值注射劑類藥物專利到期

日本製藥業正面臨專利到期潮，尤其是用於癌症治療、自體免疫疾病和代謝紊亂的高價值注射劑。在專利懸崖的背景下，非專利生產商正抓住注射劑領域的機遇，因為注射劑的價格利潤率仍然高於口服非專利。國民健康保險（NHI）體係正透過更新報銷標準和積極採用更具成本效益的替代療法來支持這項轉型。這種法規環境直接影響日本注射非專利藥的市場佔有率，尤其是在高成本的住院治療領域，使學名藥能夠更便捷地進入處方藥目錄並獲得臨床應用。大型醫院和地區醫療中心正在調整採購慣例以適應修訂後的定價模式，從而建立起優先採購可靠且價格具有競爭力的學名藥的採購流程。根據最新的2024年調查，自2021年以來，日本的監管改革促使整個行業對無菌生產技術的投資大幅增加，超過40%的受訪企業表示已主動升級設備以符合修訂後的GMP標準。日工製藥和澤井製藥等日本國內企業正抓住這些機遇，拓展注射劑產品線並提升產能。隨著原廠藥價格持續下調，學名藥在療效方面與原廠藥趨於一致，非專利注射劑的市場環境日益改善。尤其值得一提的是，2025年2月21日，中央藥品價格委員會正式核准了2025年藥品價格調整方案，該方案將於4月生效。此次調整包括強化專利到期藥的降價機制、重新評估定價標準以及提供更多獎勵以確保穩定供應，所有這些都將直接影響學名藥的定價和報銷。預計這些變化將透過加大價格壓力和支持重點製劑的持續供應，重塑日本學名藥市場的市場動態。此外，由於醫療機構採購部門日益重視供應保障和上市後監管，日本生產商也正將這些要素融入生產和物流流程，市場前景依然樂觀。

醫療機構的信任度和品質保證有助於提高醫生和病人的接受度。

在日本，保守的處方習慣歷來阻礙了非專利，尤其是注射劑的普及。根據最新的2024年報告，注射劑僅佔日本學名藥總量的6.8%，卻佔市場佔有率的26.4%，凸顯了其高成本的成本。此外，80%的注射非專利藥由僅10家公司生產，而僅有9.4%的生產設施完全符合最新標準的GMP規範。然而，隨著日本藥品和醫療設備管理局（PMDA）嚴格的監管，人們對該體系的信心正在增強。日本國內生產商正致力於確保產品品質的穩定性、透明的生產審核以及完善的藥品監測體系，這增強了醫療服務提供者的信心。這種行為轉變正促使腫瘤科、腎臟科和急診科等對非專利藥依賴性高的領域更多地採用注射劑學名藥，這些領域對臨床療效和供應可靠性要求極高，從而推動了日本注射劑非專利藥市場的整體成長。處方醫生會收到關於經濟實惠的替代藥物的電子通知，病患教育計畫也在強化已通過核准的非專利的等效性。這些變化在需要長期注射治療的領域尤其重要，因為這些領域的成本節約可以迅速累積。藥品分發獎勵和藥品目錄層面的調整正在規範當地醫療機構中學名藥的使用。在政策支持、醫院穩定需求以及臨床偏好模式的顯著轉變（尤其是對具有可靠臨床記錄和嚴格生產標準的學名藥的偏好）的推動下，日本非專利注射劑市場的長期前景正朝著有利的方向發展。

本報告解答的主要問題

日本非專利注射劑市場至今發展狀況如何？未來幾年預計又將如何發展？
日本非專利注射劑市場按治療領域分類的情況如何？
日本非專利注射劑市場按包裝類型分類的詳細情形如何？
日本非專利注射劑市場依銷售管道分類的情況如何？
日本非專利注射劑市場按地區分類的情況如何？
日本非專利注射劑市場價值鏈的不同階段有哪些？
日本非專利注射劑市場的主要促進因素和挑戰是什麼？
日本非專利注射劑市場的結構是怎麼樣的？主要企業有哪些？
日本非專利注射劑市場競爭程度如何？

The Japan generic injectables market size reached USD 1.9 Billion in 2025 . Looking forward, IMARC Group expects the market to reach USD 7.1 Billion by 2034 , exhibiting a growth rate (CAGR) of 16.05 % during 2026-2034 . Patent expirations in high-value injectables, favorable NHI reimbursement updates, expanded domestic parenteral portfolios, cost-driven procurement reforms, improved clinical acceptance, PMDA-backed regulatory confidence, electronic prescribing prompts, pharmacovigilance efforts, and increased hospital adoption across oncology, nephrology, and emergency care are some of the factors positively impacting the market.

JAPAN GENERIC INJECTABLES MARKET TRENDS:

Patent Expirations Across High-Value Injectable Drug Classes

Japan's pharmaceutical sector has entered a cycle of frequent patent expirations, particularly across high-value injectable drugs used in oncology, autoimmune diseases, and metabolic disorders. As these patent cliffs occur, generic manufacturers are seizing the opportunity to enter the injectable space, where price margins remain more favorable than oral generics. The National Health Insurance (NHI) system supports this shift by updating reimbursement rates and actively favoring cost-effective alternatives. This regulatory environment has directly influenced the Japan generic injectables market share, particularly in high-cost hospital-based therapies, giving generics significant access to formulary placement and clinical adoption. Major hospitals and regional centers are adjusting procurement practices to align with revised pricing models, resulting in procurement cycles that favor reliable and price-competitive generics. As per a recent 2024 study, regulatory reforms in Japan post-2021 have led to a notable increase in industry-wide investment in sterile manufacturing technologies, with over 40% of surveyed companies reporting active upgrades to meet revised GMP standards. Domestic companies, such as Nichi-Iko and Sawai, are leveraging these opportunities with expanded parenteral portfolios and increased capacity. With originator prices consistently revised downward and generics gaining parity in therapeutic trust, the landscape for injectable generics is strengthening. Notably, on February 21, 2025, Chuikyo formally approved the pricing rules for Japan's FY2025 drug price revision, which will come into effect in April. The revision includes tighter price reduction mechanisms for off-patent drugs, revised repricing criteria, and further incentives for stable supply, all of which directly influence generic injectable pricing and reimbursement. These changes are expected to reshape market dynamics for injectable generics in Japan by reinforcing pricing pressure while supporting supply continuity for high-priority formulations. Institutional buyers are further placing increasing emphasis on supply assurance and post-marketing monitoring, which Japanese manufacturers have integrated into their production and logistics workflows, thereby creating a positive market outlook.

Physician and Patient Acceptance Driven by Institutional Trust and Quality Assurance

In Japan, conservative prescribing patterns have historically slowed generic uptake, particularly in injectables. As per a recent 2024 report, injectables accounted for only 6.8% of Japan's generic drug volume but made up 26.4% of its market value, underscoring their high-cost concentration. Additionally, 80% of injectable generics were produced by just 10 companies, with only 9.4% of facilities meeting full GMP compliance under updated standards. However, institutional trust has grown in tandem with stringent regulatory oversight by the Pharmaceuticals and Medical Devices Agency (PMDA). Domestic manufacturers have focused on quality consistency, transparent manufacturing audits, and strong pharmacovigilance programs, which have reassured healthcare providers. This behavioral shift is contributing to the overall Japan generic injectables market growth, as it has led to broader adoption of generic injectables in high-dependency areas such as oncology, nephrology, and emergency care, where clinical outcomes and supply reliability are critical. Prescribers now receive electronic prompts for cost-effective alternatives, and patient education programs are reinforcing the equivalency of approved generics. These changes are particularly relevant in therapeutic classes requiring long-term injectable therapy cycles, where cost savings accumulate quickly. Dispensing incentives and formulary-level changes have started to normalize generic use even in community-level care settings. The long-term Japan generic injectables market outlook reflects a favorable shift, driven by supportive policy, steady demand from hospitals, and a measurable change in clinical preference patterns, especially for injectable generics with reliable clinical histories and robust manufacturing standards.

JAPAN GENERIC INJECTABLES MARKET SEGMENTATION:

Therapeutic Area Insights:

Oncology
Anesthesia
Anti-infectives
Parenteral Nutrition
Cardiovascular

Container Insights:

Vials
Ampoules
Premix
Prefilled Syringes

Distribution Channel Insights:

Hospitals
Retail Pharmacy

Regional Insights:

Kanto Region
Kansai/Kinki Region
Central/Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

KEY QUESTIONS ANSWERED IN THIS REPORT
How has the Japan generic injectables market performed so far and how will it perform in the coming years?
What is the breakup of the Japan generic injectables market on the basis of therapeutic area?
What is the breakup of the Japan generic injectables market on the basis of container?
What is the breakup of the Japan generic injectables market on the basis of distribution channel?
What is the breakup of the Japan generic injectables market on the basis of region?
What are the various stages in the value chain of the Japan generic injectables market?
What are the key driving factors and challenges in the Japan generic injectables market?
What is the structure of the Japan generic injectables market and who are the key players?
What is the degree of competition in the Japan generic injectables market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Generic Injectables Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Generic Injectables Market Landscape

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 Japan Generic Injectables Market - Breakup by Therapeutic Area

6.1 Oncology
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2020-2025)
- 6.1.3 Market Forecast (2026-2034)
6.2 Anesthesia
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2020-2025)
- 6.2.3 Market Forecast (2026-2034)
6.3 Anti-infectives
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2020-2025)
- 6.3.3 Market Forecast (2026-2034)
6.4 Parenteral Nutrition
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2020-2025)
- 6.4.3 Market Forecast (2026-2034)
6.5 Cardiovascular
- 6.5.1 Overview
- 6.5.2 Historical and Current Market Trends (2020-2025)
- 6.5.3 Market Forecast (2026-2034)

7 Japan Generic Injectables Market - Breakup by Container

7.1 Vials
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2020-2025)
- 7.1.3 Market Forecast (2026-2034)
7.2 Ampoules
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2020-2025)
- 7.2.3 Market Forecast (2026-2034)
7.3 Premix
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2020-2025)
- 7.3.3 Market Forecast (2026-2034)
7.4 Prefilled Syringes
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2020-2025)
- 7.4.3 Market Forecast (2026-2034)

8 Japan Generic Injectables Market - Breakup by Distribution Channel

8.1 Hospitals
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2020-2025)
- 8.1.3 Market Forecast (2026-2034)
8.2 Retail Pharmacy
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2020-2025)
- 8.2.3 Market Forecast (2026-2034)

9 Japan Generic Injectables Market - Breakup by Region

9.1 Kanto Region
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2020-2025)
- 9.1.3 Market Breakup by Therapeutic Area
- 9.1.4 Market Breakup by Container
- 9.1.5 Market Breakup by Distribution Channel
- 9.1.6 Key Players
- 9.1.7 Market Forecast (2026-2034)
9.2 Kansai/Kinki Region
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2020-2025)
- 9.2.3 Market Breakup by Therapeutic Area
- 9.2.4 Market Breakup by Container
- 9.2.5 Market Breakup by Distribution Channel
- 9.2.6 Key Players
- 9.2.7 Market Forecast (2026-2034)
9.3 Central/ Chubu Region
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2020-2025)
- 9.3.3 Market Breakup by Therapeutic Area
- 9.3.4 Market Breakup by Container
- 9.3.5 Market Breakup by Distribution Channel
- 9.3.6 Key Players
- 9.3.7 Market Forecast (2026-2034)
9.4 Kyushu-Okinawa Region
- 9.4.1 Overview
- 9.4.2 Historical and Current Market Trends (2020-2025)
- 9.4.3 Market Breakup by Therapeutic Area
- 9.4.4 Market Breakup by Container
- 9.4.5 Market Breakup by Distribution Channel
- 9.4.6 Key Players
- 9.4.7 Market Forecast (2026-2034)
9.5 Tohoku Region
- 9.5.1 Overview
- 9.5.2 Historical and Current Market Trends (2020-2025)
- 9.5.3 Market Breakup by Therapeutic Area
- 9.5.4 Market Breakup by Container
- 9.5.5 Market Breakup by Distribution Channel
- 9.5.6 Key Players
- 9.5.7 Market Forecast (2026-2034)
9.6 Chugoku Region
- 9.6.1 Overview
- 9.6.2 Historical and Current Market Trends (2020-2025)
- 9.6.3 Market Breakup by Therapeutic Area
- 9.6.4 Market Breakup by Container
- 9.6.5 Market Breakup by Distribution Channel
- 9.6.6 Key Players
- 9.6.7 Market Forecast (2026-2034)
9.7 Hokkaido Region
- 9.7.1 Overview
- 9.7.2 Historical and Current Market Trends (2020-2025)
- 9.7.3 Market Breakup by Therapeutic Area
- 9.7.4 Market Breakup by Container
- 9.7.5 Market Breakup by Distribution Channel
- 9.7.6 Key Players
- 9.7.7 Market Forecast (2026-2034)
9.8 Shikoku Region
- 9.8.1 Overview
- 9.8.2 Historical and Current Market Trends (2020-2025)
- 9.8.3 Market Breakup by Therapeutic Area
- 9.8.4 Market Breakup by Container
- 9.8.5 Market Breakup by Distribution Channel
- 9.8.6 Key Players
- 9.8.7 Market Forecast (2026-2034)

10 Japan Generic Injectables Market - Competitive Landscape

10.1 Overview
10.2 Market Structure
10.3 Market Player Positioning
10.4 Top Winning Strategies
10.5 Competitive Dashboard
10.6 Company Evaluation Quadrant

11 Profiles of Key Players

11.1 Company A
- 11.1.1 Business Overview
- 11.1.2 Products Offered
- 11.1.3 Business Strategies
- 11.1.4 SWOT Analysis
- 11.1.5 Major News and Events
11.2 Company B
- 11.2.1 Business Overview
- 11.2.2 Products Offered
- 11.2.3 Business Strategies
- 11.2.4 SWOT Analysis
- 11.2.5 Major News and Events
11.3 Company C
- 11.3.1 Business Overview
- 11.3.2 Products Offered
- 11.3.3 Business Strategies
- 11.3.4 SWOT Analysis
- 11.3.5 Major News and Events
11.4 Company D
- 11.4.1 Business Overview
- 11.4.2 Products Offered
- 11.4.3 Business Strategies
- 11.4.4 SWOT Analysis
- 11.4.5 Major News and Events
11.5 Company E
- 11.5.1 Business Overview
- 11.5.2 Products Offered
- 11.5.3 Business Strategies
- 11.5.4 SWOT Analysis
- 11.5.5 Major News and Events

12 Japan Generic Injectables Market - Industry Analysis

12.1 Drivers, Restraints, and Opportunities
- 12.1.1 Overview
- 12.1.2 Drivers
- 12.1.3 Restraints
- 12.1.4 Opportunities
12.2 Porters Five Forces Analysis
- 12.2.1 Overview
- 12.2.2 Bargaining Power of Buyers
- 12.2.3 Bargaining Power of Suppliers
- 12.2.4 Degree of Competition
- 12.2.5 Threat of New Entrants
- 12.2.6 Threat of Substitutes
12.3 Value Chain Analysis